Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mindfulness-Assisted Psychedelic Therapy (MAPT)
NCT06233344Phase 2Recruiting
- Sponsor
- University of Southern California
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin (2 arms), sponsored by University of Southern California. Primary endpoints: Retention at 8-week follow-up and Change in stress symptoms at 8 weeks. Started Jul 2025; status: recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT06233344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233344.